Characterization of pro-inflammatory, regulatory, and anti-inflammatory interleukins in placentas affected by acute fetal distress across gestational ages: a pilot study Authors: Elizabete Brikune, Anna Junga, Jana Brikune, Māra Pilmane Published: 2026 ABSTRACT AbstractBackgroundPregnancy requires finely regulated immunological adaptation, in which interleukins play central roles in mediating maternal–fetal communication and maintaining immune equilibrium. Acute fetal distress (distress acuta) is associated with inflammatory processes that may compromise placental function and pregnancy outcomes. The present study aimed to investigate the expression patterns and distribution of selected interleukins—IL-1α, IL-2, IL-4, IL-6, IL-7, IL-8, and IL-10—in placental tissues across three gestational stages (28, 31, and 40 weeks).MethodsA retrospective exploratory study was conducted on placental tissues obtained from 15 participants with acute fetal distress (n = 5 per group) and 5 control samples at 40 weeks of gestation. Immunohistochemical analysis with semi-quantitative assessment and nonparametric statistical methods was applied.ResultsDistressed placentas demonstrated increased expression of pro-inflammatory interleukins, particularly IL-1α, IL-2, and IL-8, compared to controls. IL-2 expression appeared to decrease toward term, while IL-7 and IL-8 showed relatively consistent activity across gestational stages. Anti-inflammatory interleukins IL-4 and IL-10 demonstrated reduced expression in distressed placentas, whereas control samples showed comparatively higher levels. In contrast, IL-6 expression remained relatively stable across gestational stages in both groups. Correlation analysis indicated coordinated interleukin expression patterns across placental compartments.ConclusionsThese findings may suggest an altered interleukin profile in placental distress acuta, characterized by a shift toward a pro-inflammatory environment. However, given the exploratory design and limited sample size, the results should be interpreted with caution, and further studies are required to confirm these observations.Keywords: Interleukins, Placental distress, Inflammation, Gestational age, Immunohistochemistry, Maternal-fetal health, IL-1α, IL-6, IL-10 Background Pregnancy represents a highly specialized physiological state characterized by finely regulated immunological adaptation. The maternal immune system must simultaneously tolerate the semi-allogeneic fetus while preserving its ability to respond to pathogens. Achieving this balance requires tightly controlled immune regulation, particularly through cytokine signaling pathways. Disruptions in this equilibrium may contribute to adverse pregnancy outcomes, including pregnancy complications or loss [1]. Both globally and in Latvia, pregnancy-related complications affecting maternal health and neonatal outcomes remain an important challenge in modern medicine. Increasing concerns have emerged regarding declining rates of successful pregnancies and live births, raising questions about the underlying mechanisms that may influence maternal–fetal health. Among the key determinants of pregnancy outcomes is placental function, as the placenta acts as the primary interface between maternal and fetal systems. This temporary but highly specialized organ facilitates nutrient and gas exchange, endocrine signaling, and immunological communication necessary for fetal development [2]. Acute fetal distress (distress acuta) represents a clinically significant condition characterized by signs of compromised fetal oxygenation and well-being, most commonly identified through abnormal cardiotocographic patterns, reduced fetal movements, or other indicators of fetal compromise. It frequently necessitates urgent obstetric intervention and is associated with increased risks of adverse perinatal outcomes. From a pathophysiological perspective, fetal distress is often linked to placental dysfunction, impaired uteroplacental perfusion, and inflammatory processes within placental tissues, which may disrupt normal maternal-fetal exchange [3]. Thus, investigation of placental tissue in the context of fetal distress may provide insight into underlying molecular and immunological mechanisms contributing to compromised pregnancy outcomes. Similar to other organs, the placenta undergoes dynamic structural and functional changes throughout gestation. During these periods of development, the tissue may become vulnerable to pathological alterations, including inflammatory processes. Cytokines play critical roles in regulating these processes and are broadly categorized into pro-inflammatory, regulatory, and anti-inflammatory mediators that collectively shape the placental immune environment. Among the principal pro-inflammatory interleukins are interleukin-1α (IL-1α), interleukin-2 (IL-2), interleukin-7 (IL-7), and interleukin-8 (IL-8), whereas interleukin-4 (IL-4) and interleukin-10 (IL-10) are generally considered anti-inflammatory mediators. Interleukin-6 (IL-6) functions as a regulatory interleukin with both pro- and anti-inflammatory properties, reflecting the complexity of immune modulation within placental tissue. Interleukin-1 (IL-1) represents a multifunctional family of interleukins involved in the regulation of inflammatory responses and tissue remodeling. It is produced by various cell types, including monocytes, macrophages, neutrophils, fibroblasts, and endothelial cells. The IL-1 family comprises two major forms, IL-1α and IL-1β, which exert similar biological effects through binding to interleukin-1 receptor type 1 (IL-1R1) and activation of downstream signaling pathways [4, 5]. Altered expression of IL-1–related pathways has been associated with pregnancy complications, including preeclampsia, suggesting its involvement in pathological inflammatory activation. Interleukin-2 (IL-2) plays a central role in T-cell–mediated immune responses and is essential for lymphocyte proliferation and differentiation. Its expression in reproductive tissues has been linked to immune activation in pathological conditions, including spontaneous abortion and preeclampsia, indicating a potential role in dysregulated maternal–fetal immune interactions [6, 7]. Interleukin-4 (IL-4) is an important immunomodulatory interleukin that promotes humoral immune responses while suppressing cellular immunity. Within placental and decidual tissues, IL-4 has been identified in multiple cellular compartments, including cytotrophoblasts and endothelial cells. Although generally considered anti-inflammatory, its role in intrauterine environments appears complex and may be context-dependent, particularly in association with pregnancy complications [8]. Interleukin-6 (IL-6) is a multifunctional interleukin involved in immune regulation, inflammation, and vascular responses. Produced by trophoblasts and immune cells, IL-6 contributes to the regulation of placental homeostasis. However, elevated IL-6 levels have been associated with increased vascular permeability and trophoblast apoptosis, suggesting a potential role in pathological conditions such as preeclampsia [9, 10]. Despite its recognized importance, its variation across different stages of placental maturation remains incompletely understood. Interleukin-7 (IL-7) is primarily involved in T-cell development and maintenance, with emerging evidence suggesting its role in pro-inflammatory responses. Its contribution to placental physiology remains less clearly defined; however, its association with Th17 cell activity indicates a possible role in inflammatory processes linked to pregnancy complications [11]. Interleukin-8 (IL-8), a chemokine with strong neutrophil-attracting properties, is expressed in various reproductive tissues, including the placenta. Its involvement in inflammatory signaling and tissue remodeling suggests a potential role in both physiological processes such as labor and pathological inflammatory activation [12]. Interleukin-10 (IL-10) is a key anti-inflammatory interleukin that suppresses pro-inflammatory responses mediated by T-helper 1 lymphocytes. It is produced by a wide range of immune and non-immune cells and plays an essential role in maintaining immune balance during pregnancy. Altered IL-10 expression has been associated with vascular dysfunction and the development of pregnancy-related complications such as preeclampsia [10, 13]. Despite the growing body of research investigating interleukin involvement in placental physiology and pathology, important gaps in knowledge remain. Although individual interleukins have been associated with specific placental disorders, limited information is available regarding their coordinated expression patterns and dynamic changes during different stages of placental development. Therefore, the present study aims to investigate the expression patterns and distribution of pro-inflammatory, regulatory, and anti-inflammatory interleukins in placental tissues affected by acute fetal distress (distress acuta) across different stages of gestation, in order to better understand immunological alterations associated with this pathological condition. In addition, the study seeks to explore potential relationships between interleukin expression and specific placental structural components. Methods Study participants This study was conducted as a retrospective observational analysis of 15 archived placental tissue samples. The study included placentas obtained at three gestational stages: the 28th, 31st, and 40th weeks of pregnancy. All samples were retrieved from the archive of the Institute of Anatomy and Anthropology, Riga Stradiņš University. The placental material had originally been collected at the Riga Maternity Hospital between 2005 and 2010. Written informed consent was obtained from all participants prior to delivery and inclusion in the study. Each participant received a detailed explanation of the study objectives and procedures before signing the consent form permitting both participation and the use of collected data for scientific publication. The research was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki. The study protocol was reviewed and approved by the Ethics Committee of Riga Stradiņš University on 12 March 2003. Characteristics of selected patients A total of fifteen pregnant women aged between 20 and 39 years were included in the study. Regarding gravidity, six participants were experiencing their first pregnancy (gravida I), three were in their second pregnancy, two were in their third pregnancy, three were in their fourth pregnancy, and one participant was in her sixth pregnancy. In terms of parity, ten women delivered for the first time (para I), four had their second delivery, and one participant had her third delivery. The participants and their corresponding placental samples were categorized according to gestational age at delivery. Group classification followed the World Health Organization definition of preterm birth based on gestational age at the time of delivery [14]: Full-term infants – GA between 37 weeks and 41 week and 6 days; Full-term infants – GA between 37 weeks and 41 week and 6 days; Late preterm infants – GA between 34 weeks and 36 weeks and 6 days; Late preterm infants – GA between 34 weeks and 36 weeks and 6 days; Moderate preterm infants – GA between 32 weeks and 33 weeks and 6 days; Moderate preterm infants – GA between 32 weeks and 33 weeks and 6 days; Very preterm infants – GA < 32 weeks. Very preterm infants – GA < 32 weeks. Extremely preterm infants – GA < 28 weeks. Extremely preterm infants – GA < 28 weeks. Abbreviations: GA – gestational age. Abbreviations: GA – gestational age. According to the classification described above, the participants were divided into three groups. The first group included five cases of extremely preterm deliveries occurring at the 28th gestational week. The second group consisted of five cases of very preterm deliveries at the 31st gestational week. The third group comprised five term deliveries at the 40th gestational week. Although the pregnancy outcomes varied among the groups, all fifteen cases shared a common clinical characteristic - acute fetal distress (distress acuta). Cases of “placental distress (distress acuta)” were defined based on retrospective clinical classification of acute fetal distress as documented in obstetric medical records. The diagnosis was established by the attending obstetrician using intrapartum clinical assessment, primarily including abnormal cardiotocographic findings suggestive of fetal compromise, reduced fetal well-being, and clinical indications for urgent obstetric intervention according to intrapartum fetal monitoring guidelines [15–17]. Additional clinical signs considered during case evaluation included persistent fetal heart rate abnormalities, suspected fetal hypoxia, and other indicators of compromised fetal condition identified during labor management. Because universally standardized diagnostic criteria for acute fetal distress remain limited and clinical interpretation may vary between institutions, all cases were selected from clinically confirmed diagnoses documented in patient records. Detailed clinical and obstetric information for the participating women and the complications associated with their deliveries are presented in Table 1. Table 1Info about the patientsNo.Female ageGraviditasPartusDelivery week/problems7.36II28, Spontaneous preterm delivery, distress acuta14.20II28, Fetus premature pathology, distress acuta19.31IIII28, Spontaneous preterm delivery, distress acuta20.26II28, Spontaneous preterm delivery, distress acuta24.36III28, Spontaneous preterm delivery, distress acuta22.36IIII31, Partum premature operationis, distress acuta23.39VIII31, Partum premature operationis, distress acuta26.36II31, Spontaneous preterm delivery, distress acuta32.28IVI31, Spontaneous preterm delivery, distress acuta33.28IVI31, Spontaneous preterm delivery, distress acuta2.39IVII40, Partus mature, distress acuta9.27IIIIII40, Partus mature, distress acuta10.23II40, Partus mature, distress acuta13.31IIII40, Partus mature operationis, distress acuta16.22II40, Partus mature, distress acuta Info about the patients Eligibility criteria Placental tissue samples were selected from the institutional archive based on predefined inclusion and exclusion criteria. Inclusion criteria were: retrospective clinical diagnosis of fetal distress documented in obstetric medical records; singleton pregnancy; absence of previously diagnosed pregnancy complications; gestational age at delivery corresponding to one of the predefined groups (28, 31, or 40 weeks); availability of adequately preserved placental tissue suitable for histological and immunohistochemical analysis. Exclusion criteria included: presence of chronic maternal diseases (e.g., diabetes mellitus, chronic hypertension, autoimmune disorders); clinically or laboratory-confirmed specific infections during pregnancy; multiple pregnancy; known congenital fetal anomalies; insufficient or poor-quality tissue samples. Selection criteria of control tissue samples Control placental samples were obtained from uncomplicated singleton pregnancies delivered at term (40 weeks gestation). Inclusion criteria for controls included absence of fetal distress, no maternal chronic diseases or clinically significant infections, and normal pregnancy course. Only well-preserved tissue samples suitable for histological and immunohistochemical analysis were included. Gestational age-matched controls for preterm groups were not available due to ethical limitations, as collection of placental tissue from healthy pregnancies at earlier gestational ages would require unjustified clinical intervention. These samples were also obtained from the archive of the Institute of Anatomy and Anthropology, Riga Stradiņš University. Sample collection Immediately after delivery, placental tissue samples were collected from the maternal surface of the placenta. Specimens were obtained from three locations across the full thickness of the placental tissue: one central region near the umbilical cord insertion and two peripheral regions. Each tissue sample measured no more than 2.2 cm in diameter and approximately 2.2 mm in thickness. Following collection, the samples were fixed to preserve tissue architecture and stabilize cellular structures. Tissue fixation was performed using 10% buffered formalin for 2 h at room temperature, followed by an additional 2–4 h in a thermostat maintained at 39–41 °C. In addition, Stefanini’s fixative solution, consisting of formaldehyde, buffer, and picric acid, was used in our laboratory protocol. After fixation, the samples were washed in Tyrode’s solution. Subsequently, the prepared placental specimens were transported to the Institute of Anatomy and Anthropology, Riga Stradiņš University, for further histological processing. Routine staining Following fixation, the tissue samples underwent dehydration through a graded ethanol series (70%, 80%, 96%, and absolute ethanol (100%)) to ensure complete removal of water from the specimens. This was followed by clarification in xylene and subsequent paraffin infiltration and embedding according to standard histological procedures. Paraffin embedding was performed using specialized equipment, with the volume of paraffin regulated by a dispenser to ensure uniform embedding of the tissue samples. The paraffin blocks were subsequently sectioned using a Leica microtome to obtain tissue sections measuring 3–5 μm in thickness. The sections were then deparaffinized in xylene for 5–15 min and rehydrated through a descending ethanol series (100%, 96%, 80%, and 70%), followed by rinsing in distilled water. For histological evaluation, the sections were stained with hematoxylin for 1–10 min and with eosin for 30 s to 1 min. Following staining, sections were dehydrated through an ascending ethanol series, cleared in xylene, and mounted with coverslips using a standard mounting medium to complete the preparation of the histological specimens. Immunohistochemical (IHC) analysis Immunohistochemical analysis was performed on serial sections obtained from the same formalin-fixed, paraffin-embedded placental tissue blocks used for routine histological staining. Hematoxylin and eosin staining and immunohistochemistry were carried out on separate sections to ensure methodological accuracy. Placental tissue sections obtained from both the central region near the umbilical cord insertion and peripheral regions were prepared for immunohistochemical analysis using the standard streptavidin–biotin immunostaining technique [18]. Thiilar semi-quantito detect the presence and distribution of seven different interleukins in placental tissues: IL-1α (orb308737, polyclonal, working dilution 1:100, Biorbyt LTD, Cambridge, UK); IL-1α (orb308737, polyclonal, working dilution 1:100, Biorbyt LTD, Cambridge, UK); IL-2 (ab92381, monoclonal, working dilution 1:250, Abcam, Cambridge, UK); IL-2 (ab92381, monoclonal, working dilution 1:250, Abcam, Cambridge, UK); IL-4 (orb10908, polyclonal, working dilution 1:100, Biorbyt LTD, Cambridge, UK); IL-4 (orb10908, polyclonal, working dilution 1:100, Biorbyt LTD, Cambridge, UK); IL-6 (ab216492, polyclonal, working dilution 1:200, Abcam, Cambridge, UK); IL-6 (ab216492, polyclonal, working dilution 1:200, Abcam, Cambridge, UK); IL-7 (orb13506, polyclonal, working dilution 1:100, Biorbyt LTD, Cambridge, UK); IL-7 (orb13506, polyclonal, working dilution 1:100, Biorbyt LTD, Cambridge, UK); IL-8 (orb39299, polyclonal, working dilution 1:100, Biorbyt LTD, Cambridge, UK); IL-8 (orb39299, polyclonal, working dilution 1:100, Biorbyt LTD, Cambridge, UK); IL-10 (ab134742, monoclonal, working dilution 1:50, Abcam, Cambridge, UK). IL-10 (ab134742, monoclonal, working dilution 1:50, Abcam, Cambridge, UK). Paraffin-embedded tissue sections (approximately 3 μm in thickness) were prepared, deparaffinized in xylene, and rehydrated through a graded ethanol series to distilled water. Antigen retrieval was performed using heat-induced epitope retrieval in an appropriate buffer solution according to standard protocols. Antibodies were diluted to the required working concentration using an antibody diluent (code 938B-05, Cell Marque™, Rocklin, CA, USA). Primary antibodies were applied to the sections according to the manufacturer’s recommended protocol. After incubation with the primary antibody, the sections were rinsed with IHC wash buffer. The HiDef Detection™ Amplifier (code 954D-31, Cell Marque™, Rocklin, CA, USA) was then applied for 10 min at room temperature, followed by washing with IHC wash buffer. Subsequently, the HiDef Detection™ HRP Polymer Detector (code 954D-32, Cell Marque™, Rocklin, CA, USA) was applied for 10 min at room temperature, followed by another washing step. An HRP-compatible chromogen was applied according to the manufacturer’s instructions to visualize the antigen–antibody reaction, after which the sections were rinsed with distilled or deionized water. The slides were then counterstained, dehydrated, cleared, and mounted with coverslips for microscopic analysis. Negative control slides were prepared using the same staining procedure but without the application of primary antibodies. Semi-quantitative assessment of interleukin expression The histological slides were independently evaluated by two experienced morphologists. A semi-quantitative assessment combined with light microscopy was used to determine the relative number of IL-1α, IL-2, IL-4, IL-6, IL-7, IL-8, and IL-10 positive structures within placental tissue sections. Specifically, immunoreactivity was assessed in cytotrophoblasts, extraembryonic mesoderm, macrophages, and endothelial cells. For the evaluation of positively stained structures within each microscopic field, a semi-quantitative scoring system was applied. The identifiers and scoring criteria used for this assessment are summarized in Table 2 [19, 20]. Similar semi-quantitative scoring systems have been widely applied in studies evaluating peptide and protein expression in human tissues [21–23]. Table 2The semi-quantitative counting method and the explanation of the identifiersIdentifier usedExplanation0No immunopositive cells in the visual field (0)0/+Occasional occurrence of immunopositive cells in the visual field (0,5)+Few immunopositive cells in the visual field (1)++Moderate occurrence of immunopositive cells in the visual field (2)+++Numerous immunopositive cells in the visual field (3)++++Abundant immunopositive cells in the visual field (4) The semi-quantitative counting method and the explanation of the identifiers Statistical analysis Descriptive statistical analysis was performed for all study groups based on the relative cytokine expression values obtained through the semi-quantitative evaluation method. Statistical data processing and analysis were conducted using IBM SPSS Statistics software, version 29.0 (IBM Corp., Armonk, NY, USA). Median values were used to describe the distribution of each parameter. To compare interleukin expression across different placental structures - including cytotrophoblasts, extraembryonic mesoderm, macrophages, and endothelial cells - between placentas from different gestational ages, the Independent-Samples Kruskal-Wallis test was applied. This non-parametric test was selected because the semi-quantitative scoring system produced ordinal data. A p-value of < 0.05 was considered statistically significant. Given the small sample size and exploratory design of the study, no post hoc multiple comparison tests were performed. Associations between cytokine expression levels and placental structures were evaluated using Spearman’s rank correlation analysis [24]. Correlation analyses were performed both between different cytokines and between cytokine expression and specific placental structures (cytotrophoblasts, extraembryonic mesoderm, macrophages, and endothelium). Spearman’s rho coefficient was used to assess the strength and direction of these relationships, allowing evaluation of how changes in the expression of one cytokine may relate to variations in others across the examined placental structures. The strength of correlations was interpreted according to the following criteria: rs values of 0.00–0.24 indicated a very weak correlation, 0.25–0.49 a weak correlation, 0.50–0.74 a strong correlation, and 0.75–1.00 a very strong correlation. Results Routine staining The samples showed practically similar changes and features of placental structures - a lot of fibrinoid deposits and huge infiltration of the macrophages, also known as Hofbauer cells. All placentas corresponded to transitional stages and showed signs of aging. In some cases, lymphocyte infiltration and obliterated blood vessels were observed (Fig. 1a–b). Hematoxylin and eosin staining of the 28th and 40th delivery week (the case group) patient tissue samples.(a) Note the maternal part of placenta with abundance of Hofbauer cells (arrows). 100x; (b) note fibrinoid deposits and practically unchanged placental structures (arrows). 100x IL-1α IHC IL-1α expression was observed across all placental compartments in both preterm and term distressed groups, with generally high levels in cytotrophoblasts, extraembryonic mesoderm, and endothelial cells. In the 28th and 31st gestational week groups, IL-1α immunopositivity was consistently abundant in most compartments, including macrophages, although some inter-sample variability was noted. At 40 weeks of gestation, similarly elevated IL-1α expression was observed in cytotrophoblasts, mesoderm, and endothelium; however, macrophage positivity appeared reduced compared to earlier gestational groups and showed greater variability between samples. In contrast, control placentas at 40 weeks demonstrated overall lower IL-1α expression, particularly in endothelial cells and macrophages, where minimal or absent staining was frequently observed. Cytotrophoblast and mesoderm compartments exhibited only low-to-moderate levels of immunopositivity. Detailed semi-quantitative data are presented in Table 3; Fig. 2a–d. Table 3Semi-quantitative data analysis of the IL-1α and IL-2 cytokinesFactorIL-1 alphaIL-2TissueCytot.E.m.Ma.End.Cytot.E.m.Ma.End.GroupMedian value28 weeks +++ +++ +++ ++ +++ +++ +++ +++ 31 weeks ++ +++ +++ +++ ++ ++ ++++ ++ 40 weeks +++ +++ + +++ + + + +/0 Controls of 40 weeks + ++ 0 +/0 +/0 +/0 0 0 Abbreviations: Cytot. Cytotrophoblast, E.m. Extraembryonic Mesoderm, Ma. Macrophages, End. Endothelium, IL-1α Interleukin 1 α, IL-2 Interleukin 2, IMH Immunohistochemistry0 - no staining, 0/+ - occasional occurrence of positive structures, + - few positive structures, ++ - moderate occurrence, +++ - numerous positive structures, ++++ - abundant staining Semi-quantitative data analysis of the IL-1α and IL-2 cytokines Abbreviations: Cytot. Cytotrophoblast, E.m. Extraembryonic Mesoderm, Ma. Macrophages, End. Endothelium, IL-1α Interleukin 1 α, IL-2 Interleukin 2, IMH Immunohistochemistry 0 - no staining, 0/+ - occasional occurrence of positive structures, + - few positive structures, ++ - moderate occurrence, +++ - numerous positive structures, ++++ - abundant staining Immunohistochemistry of the IL-1α positive structures in the patient tissue samples. (a) Numerous positive for factor cytotrophoblastic cells and moderate positive Hofbauer cells (arrows) in the villi of the 28 weeks old placenta. IL-1α IHC, 200x; (b) numerous IL-1α positive extraembryonic mesoderm and blood vessel cells (arrows) of the 31 weeks old placenta. IL-1α IHC, 200x; (c) moderate IL-1α positive cytotrophoblast, extraembryonic mesoderm cells and endothelium structures of the 40 weeks old placenta (arrows). IL-1α IHC, 200x; (d) moderate positive for factor cytotrophoblastic cells (arrows), extraembryonic mesoderm and moderate positive Hofbauer cells (arrows) in the villi of the control group placenta of 40 weeks. IL-1α IHC, 200x A comparison of the IL-1α positive cytotrophoblast (p = 0.721), extraembryonic mesoderm (p = 0.534), macrophages (p = 0.141) and endothelium (p = 0.393) across all patient groups with different delivery weeks using the Independent-Samples Kruskal-Wallis Test illustrated no statistically significant differences between the different time placentas. IL-2 IHC IL-2 expression showed a clear decrease across advancing gestational age in distressed placentas. In the 28th gestational week group, IL-2 immunopositivity was generally high across all examined placental compartments, including cytotrophoblasts, extraembryonic mesoderm, endothelium, and macrophages, although variability between samples was observed. At 31 weeks of gestation, IL-2 expression was moderately reduced in most tissue compartments compared to the earlier gestational group, while macrophages exhibited relatively higher levels of immunopositivity. By 40 weeks of gestation, IL-2 expression was markedly decreased across all compartments, with only low levels detected in cytotrophoblasts, mesoderm, and macrophages, and minimal expression in endothelial cells. In contrast, control placentas at 40 weeks demonstrated little to no IL-2 expression, with only occasional immunopositive cells observed in selected compartments. Detailed semi-quantitative data are presented in Table 3; Fig. 3a–d. Immunohistochemistry of the IL-2 positive structures in the patient tissue samples. (a) Numerous positive for factor cytotrophoblastic and endothelium cells (arrows) and moderate positive Hofbauer cells in the villi of the 28 weeks old placenta. IL-2 IHC, 200x; (b) abundance of macrophages and numerous IL-2 positive cytotrophoblast (arrows), endothelium and extraembryonic mesoderm cells of the 31 weeks old placenta. IL-2 IHC, 200x; (c) moderate IL-2 positive cytotrophoblast, extraembryonic mesoderm cells and endothelium structures (arrows) in the villi of the 40 weeks old placenta. IL-2 IHC, 200x; (d) moderate occurrence of positive for factor cytotrophoblastic cells (arrows) and extraembryonic mesoderm cells (arrows), and occasional occurrence of positive for factor endothelium (arrows) in the villi of the control group placenta of 40 weeks. IL-2 IHC, 200x A comparison of the IL-2 positive extraembryonic mesoderm (p = 0.074), macrophages (p = 0.208) and endothelium cells (p = 0.100) across all patient groups with different delivery weeks using the Independent-Samples Kruskal-Wallis Test illustrated no statistically significant differences between the different time placentas, but a statistically significant difference in the structures of the positive cytotrophoblast (p = 0.011) between 28 weeks and 40 weeks (the case group) of gestation (Table 4). Table 4Comparison of the IL-2 positive cytotrophoblast, extraembryonic mesoderm, macrophages and endothelium cells between patient groups with different delivery weeksPairwise Comparisons of the IL-2 positive structures in the cytotrophoblast across three delivery weeksSamplesTest StatisticStd. ErrorStd.Test StatisticSig.Adj. Sig.a40weeks(the case group)-31 weeks4,7002,7261,7240,0850,25440weeks(the case group)-28 weeks7,9002,7262,8990,0040,01131weeks-28 weeks3,2002,7261,1740,2400,721Abbreviations: IL-2 Interleukin 2, Std. Error standard error, Std. Test Statistic – standard test statistic, Sig. Significance, Adj. Sig.a Adjusted significance Comparison of the IL-2 positive cytotrophoblast, extraembryonic mesoderm, macrophages and endothelium cells between patient groups with different delivery weeks Abbreviations: IL-2 Interleukin 2, Std. Error standard error, Std. Test Statistic – standard test statistic, Sig. Significance, Adj. Sig.a Adjusted significance IL-7 IHC IL-7 expression was generally low across all placental compartments, with modest variability between gestational groups. In the 28th gestational week group, IL-7 immunopositivity was limited in cytotrophoblasts, extraembryonic mesoderm, and endothelial cells, while macrophages demonstrated relatively higher levels of expression. At 31 weeks of gestation, a moderate increase in IL-7 expression was observed in cytotrophoblasts, mesoderm, and macrophages compared to the earlier gestational group, whereas endothelial expression remained low. By 40 weeks of gestation, IL-7 expression was again reduced across most compartments, with only minimal immunopositivity detected in cytotrophoblasts, mesoderm, and endothelium. Macrophages showed slightly higher but still variable expression. In control placentas, IL-7 expression was largely absent or minimal in endothelial and macrophage compartments, while low levels were observed in cytotrophoblasts and extraembryonic mesoderm. Detailed semi-quantitative data are presented in Table 5; Fig. 4a–d. Table 5Semi-quantitative data analysis of the IL-7 and IL-8 cytokinesFactorIL-7IL-8TissueCytot.E.m.Ma.End.Cytot.E.m.Ma.End.GroupMedian value28 weeks +/0 +/0 ++ +/0 +++ ++ ++ + 31 weeks ++ ++ ++ + ++ +++ ++ ++ 40 weeks +/0 +/0 + +/0 ++ ++ + + Controls of 40 weeks + + 0 0 ++ ++ + + Abbreviations: Cytot. Cytotrophoblast, E.m. Extraembryonic Mesoderm, Ma. Macrophages, End. Endothelium, IL-7 Interleukin 7, IL-8 Interleukin 8, IMH Immunohistochemistry0 - no staining; 0/+ - occasional occurrence of positive structures; + - few positive structures; ++ - moderate occurrence; +++ - numerous positive structures; ++++ - abundant staining; Semi-quantitative data analysis of the IL-7 and IL-8 cytokines Abbreviations: Cytot. Cytotrophoblast, E.m. Extraembryonic Mesoderm, Ma. Macrophages, End. Endothelium, IL-7 Interleukin 7, IL-8 Interleukin 8, IMH Immunohistochemistry 0 - no staining; 0/+ - occasional occurrence of positive structures; + - few positive structures; ++ - moderate occurrence; +++ - numerous positive structures; ++++ - abundant staining; Immunohistochemistry of the IL-7 positive structures in the patient tissue samples. (a) Occasional occurrence of the IL-7 positive extraembryonic mesoderm cells and macrophages (arrows) in the visual field of the 28 weeks old placenta. IL-7 IHC, 200x; (b) moderate occurrence of the IL-7 positive extraembryonic mesoderm cells, cytotrophoblast and macrophages (arrows) in the visual field of the 31 weeks old placenta. IL-7 IHC, 200x; (c) few positive structures of the cytotrophoblast (arrows) and occasional occurrence of the extraembryonic mesoderm cells and endothelium positive structures of the IL-7 in the visual field of the 40 weeks old placenta. IL-7 IHC, 200x; (d) moderate occurrence of positive for factor cytotrophoblastic cells (arrows) and extraembryonic mesoderm cells (arrows), and few positive for factor macrophages (arrows) and endothelial cells in the villi of the control group placenta of 40 weeks. IL-7 IHC, 200x A comparison of the IL-7 positive cytotrophoblast (p = 0.459), extraembryonic mesoderm (p = 0.060), macrophages (p = 0.730) and endothelium cells (p = 0.593) across all patient groups with different delivery weeks using the Independent-Samples Kruskal-Wallis Test illustrated no statistically significant differences between the different time placentas. IL-8 IHC IL-8 expression was consistently present across all placental compartments and gestational groups, without a clear linear trend related to gestational age. In the 28th gestational week group, IL-8 immunopositivity was prominent in cytotrophoblasts and variably expressed in extraembryonic mesoderm, endothelium, and macrophages. At 31 weeks of gestation, IL-8 expression remained elevated, particularly in the extraembryonic mesoderm, where the highest levels were observed among the analyzed compartments. Other cell types, including cytotrophoblasts, macrophages, and endothelial cells, demonstrated moderate but variable expression. By 40 weeks of gestation, IL-8 expression was moderately preserved in cytotrophoblasts and mesoderm, while lower levels were observed in endothelial cells and macrophages. Control placentas at 40 weeks exhibited a comparable pattern in cytotrophoblasts and mesoderm; however, expression in endothelial cells and macrophages was generally lower. Detailed semi-quantitative data are presented in Table 5; Fig. 5a–d. Immunohistochemistry of the IL-8 positive structures in the patient tissue samples. (a) Numerous positive structures of the IL-8 in the visual field of the cytotrophoblast and macrophages (arrows) of the 28 weeks old placenta. IL-8 IHC, 200x; (b) numerous positive for factor cytotrophoblastic, extraembryonic mesoderm, endothelium cells (arrows) and moderate positive Hofbauer cells in the villi of the 31 weeks old placenta. IL-8 IHC, 200x; (c) moderate occurrence of the IL-8 positive structures in the visual field of the cytotrophoblast and extraembyonic mesoderm (arrows) of the 40 weeks old placenta. IL-8 IHC, 200x; (d) occasional occurrence of positive for factor macrophages (arrows) and few positive extraembryonic mesoderm and endothelial cells (arrows) in the villi of the control group placenta of 40 weeks. IL-8 IHC, 200x A comparison of the IL-8 positive cytotrophoblast (p = 0.383), extraembryonic mesoderm (p = 0.142), macrophages (p = 0.732), and endothelium cells (p = 0.378) between the all patient groups with different delivery weeks using the Independent-Samples Kruskal-Wallis Test illustrated no statistically significant differences between the different time placentas. IL-4 IHC IL-4 expression was generally low across all placental compartments and gestational groups. In the 28th and 31st gestational week groups, IL-4 immunopositivity was minimal or absent in most cell types, including cytotrophoblasts, endothelial cells, and macrophages, with only occasional staining observed in extraembryonic mesoderm. At 40 weeks of gestation, IL-4 expression remained low, with only occasional immunopositive cells detected across most compartments, although macrophages demonstrated slightly higher levels compared to earlier gestational groups. In contrast, control placentas at 40 weeks exhibited relatively higher IL-4 expression, with low-to-moderate levels observed in cytotrophoblasts, mesoderm, and endothelium, and occasional positivity in macrophages. Detailed semi-quantitative data are presented in Table 6; Fig. 6a–d. Table 6Semi-quantitative data analysis of the IL-4, IL-10 and IL-6 cytokinesFactorIL-4IL-10IL-6TissueCytot.E.m.Ma.End.Cytot.E.m.Ma.End.Cytot.E.m.Ma.End.GroupMedian value28 weeks 0 +/0 0 0 0 0 0 0 + + ++ + 31 weeks 0 +/0 +/0 0 0 +/0 +/0 0 ++ + ++ + 40 weeks +/0 +/0 + +/0 0 +/0 0 0 +/0 + ++ + Controls of 40 weeks + + +/0 + ++ ++ + ++ + + 0 + Abbreviations: Cytot. Cytotrophoblast, E.m. Extraembryonic Mesoderm, Ma. Macrophages, End. Endothelium, IL-4 Interleukin 4, IL-10 Interleukin 10, IL-6 Interleukin 6, IMH Immunohistochemistry0 - no staining; 0/+ - occasional occurrence of positive structures; + - few positive structures; ++ - moderate occurrence; +++ - numerous positive structures; ++++ - abundant staining Semi-quantitative data analysis of the IL-4, IL-10 and IL-6 cytokines Abbreviations: Cytot. Cytotrophoblast, E.m. Extraembryonic Mesoderm, Ma. Macrophages, End. Endothelium, IL-4 Interleukin 4, IL-10 Interleukin 10, IL-6 Interleukin 6, IMH Immunohistochemistry 0 - no staining; 0/+ - occasional occurrence of positive structures; + - few positive structures; ++ - moderate occurrence; +++ - numerous positive structures; ++++ - abundant staining Immunohistochemistry of the IL-4 positive structures in the patient tissue samples. (a) None IL-4 positive structures (arrows), except some occasional positive for factor extraembryonic mesoderm cells of the 28 weeks old placenta. IL-4 IHC, 200x; (b) occasional positive for factor extraembryonic mesoderm and Hofbauer cells, and no IL-4 positive cytotrophoblastic and endothelium cells (arrows) in the villi of the 31 weeks old placenta. IL-4 IHC, 200x; (c) few positive macrophages (arrows) and occasional IL-4 positive cytotrophoblast, endothelium and extraembryonic mesoderm cells of the 40 weeks old placenta. IL-4 IHC, 200x; (d) numerous occurrence of positive for factor extraembryonic mesoderm cells (arrows), moderate cytotrophoblastic cells and few positive endothelial cells (arrows) in the villi of the control group placenta of 40 weeks. IL-4 IHC, 200x A comparison of the IL-4 positive endothelium cells (p = 0.028) and macrophages (p = 0.022) across all patient groups with different delivery weeks using the Independent-Samples Kruskal-Wallis Test illustrated a statistically significant difference between 40 weeks (the case group) and 28 weeks of delivery, and also no statistically significant differences between the positive structures of the cytotrophoblast (p = 0.131) and extraembryonic mesoderm (p = 0.158) (Table 7). Table 7Comparison of the IL-4 positive cytotrophoblast, extraembryonic mesoderm, macrophages and endothelium cells between patient groups with different delivery weeksPairwise Comparisons of the IL-4 positive macrophages across three delivery weeksSamplesTest StatisticStd. ErrorStd.Test StatisticSig.Adj. Sig.a28weeks-31 weeks-3,6002,569-1,4010,1610,48328weeks-40 weeks (the case group)-6,9002,569-2,6860,0070,02231weeks-40 weeks (the case group)-3,3002,569-1,2850,1990,597Pairwise Comparisons of the IL-4 positive structures in the endothelium across three delivery weeks28weeks-31 weeks-1,4002,345-0,5970,5511,00028weeks-40 weeks (the case group)-6,1002,345-2,6010,0090,02831weeks-40 weeks (the case group)-4,7002,345-2,0040,0450,135Abbreviations: IL-4 Interleukin 4, Std. Error Standard error, Std. Test Statistic Standard test statistic, Sig. Significance, Adj. Sig.a - Adjusted significance Comparison of the IL-4 positive cytotrophoblast, extraembryonic mesoderm, macrophages and endothelium cells between patient groups with different delivery weeks Abbreviations: IL-4 Interleukin 4, Std. Error Standard error, Std. Test Statistic Standard test statistic, Sig. Significance, Adj. Sig.a - Adjusted significance IL-10 IHC IL-10 expression was largely absent in distressed placentas across all gestational groups. In the 28th gestational week group, no IL-10 immunopositivity was detected. Similarly, at 31 and 40 weeks of gestation, IL-10 expression remained minimal, with only occasional positive cells observed in extraembryonic mesoderm and rarely in macrophages, while cytotrophoblasts and endothelial cells showed little to no staining. In contrast, control placentas at 40 weeks demonstrated noticeably higher IL-10 expression across all examined compartments, including cytotrophoblasts, mesoderm, and endothelium, with additional positivity observed in macrophages. Detailed semi-quantitative data are presented in Table 6; Fig. 7a–d. Immunohistochemistry of the IL-10 positive structures in the patient tissue samples. (a) None IL-10 positive structures of the 28 weeks old placenta (arrows). IL-10 IHC, 200x; (b) occasional positive for factor extraembryonic mesoderm and Hofbauer cells (arrows) in the villi of the 31 weeks old placenta. IL-10 IHC, 200x; (c) none IL-10 positive cytotrophoblast, macrophages, endothelium, and occasional positive for factor extraembryonic mesoderm cells (arrows) of the 40 weeks old placenta. IL-10 IHC, 200x; (d) numerous positive for factor extraembryonic mesoderm cells (arrows), cytotrophoblastic cells and macrophages (arrows), and moderate positive endothelial cells (arrows) in the villi of the control group placenta of 40 weeks. IL-10 IHC, 200x A comparison of the IL-10 positive cytotrophoblast (p = 0.280), extraembryonic mesoderm (p = 0.097), macrophages (p = 0.131) and endothelium cells (p = 0.280) across all patient groups with different delivery weeks using the Independent-Samples Kruskal-Wallis Test illustrated no statistically significant differences. IL-6 IHC IL-6 expression was generally higher and more consistently detected across all groups compared to other interleukins. In the 28th and 31st gestational week groups, IL-6 immunopositivity was present across all placental compartments, with moderate expression observed particularly in cytotrophoblasts and macrophages, although variability between samples was noted. At 40 weeks of gestation, IL-6 expression remained detectable in all compartments, with moderate levels observed in macrophages and lower but persistent expression in cytotrophoblasts, extraembryonic mesoderm, and endothelium. In control placentas, IL-6 expression was present at low levels in most compartments, while macrophages showed minimal or absent staining compared to distressed groups. Detailed semi-quantitative data are presented in Table 6; Fig. 8a–d. Immunohistochemistry of the IL-6 positive structures in the patient tissue samples. (a) Numerous positive for factor cytotrophoblastic and extraembryonic cells (arrows) and moderate positive Hofbauer and endothelium cells in the villi of the 28 weeks old placenta. IL-6 IHC, 200x; (b) abundance of the IL-6 positive macrophages in the visual field of the 31 weeks old placenta (arrows). IL-6 IHC, 200x; (c) occasional occurrence of the IL-6 positive cytotrophoblast, extraembryonic mesoderm and endothelium cells (arrows) in the villi of the 40 weeks old placenta. IL-6 IHC, 200x; (d) numerous positive for factor extraembryonic mesoderm cells (arrows) and cytotrophoblastic cells (arrows) in the villi of the control group placenta of 40 weeks. IL-6 IHC, 200x A comparison of the IL-6 positive cytotrophoblast (p = 0.423), extraembryonic mesoderm (p = 0.534), macrophages (p = 0.732), and endothelium cells (p = 0.453) across all patient groups with different delivery weeks using the Independent-Samples Kruskal-Wallis Test illustrated no statistically significant differences. Correlation analysis of interleukin expression in placental tissue across gestational groups Correlation analysis revealed multiple significant associations between interleukin expression and placental compartments. Overall, the strongest positive correlations were observed within the same interleukin across different placental structures, particularly between cytotrophoblasts, extraembryonic mesoderm, and endothelial cells. IL-2, IL-7, and IL-10 demonstrated the most consistent and strongest correlations across placental compartments, suggesting coordinated expression patterns within these tissues. Similarly, IL-6 showed stable positive associations between cytotrophoblasts, mesoderm, and endothelium. Macrophage-associated correlations were particularly prominent, with several interleukins, including IL-1α, IL-2, IL-7, IL-8, IL-6, and IL-10, demonstrating positive relationships within this cell population, indicating a potentially important role of macrophages in interleukin co-expression patterns. In contrast, negative correlations were limited and primarily involved inverse relationships between IL-7 and IL-1α, as well as between IL-2 and IL-4, suggesting possible opposing regulatory tendencies among selected interleukins. Overall, the correlation matrix highlights a predominance of positive associations, with several strong and very strong correlations observed across placental compartments, supporting the presence of coordinated interleukin expression patterns. Detailed correlation coefficients are provided in Fig. 9. The Correlation Matrix of Significant Cytokine Relationships Discussion A relative increase in pro-inflammatory interleukins, including IL-1α, IL-2, and IL-8, was observed in placental samples obtained at 28 weeks of gestation. The expression of these interleukins appeared to decrease in placentas collected at 40 weeks of gestation and was lowest in the control group. In contrast, anti-inflammatory interleukins IL-4 and IL-10 demonstrated reduced or absent expression across most placental structures in the patient groups at different gestational stages. Comparatively higher levels of IL-4 and IL-10 positivity were observed in control placentas obtained at 40 weeks of gestation. In the present study, IL-1α showed a consistent increase within the endothelium and extraembryonic mesoderm across all examined gestational groups. These findings may suggest that IL-1α could be involved in inflammatory processes in placentas affected by distress acuta, regardless of gestational age. By binding to the interleukin-1 receptor (IL-1R), IL-1α may contribute to the amplification of inflammatory signaling and promote the production of additional inflammatory mediators. Previous studies have reported that IL-1 was among the first interleukins implicated in preterm labor associated with inflammation [25]. Supporting this, IL-1α has been shown to be produced by the human decidua in response to bacterial stimuli and to induce prostaglandin production in the amnion and decidua. Elevated IL-1α concentrations and activity have also been described in the amniotic fluid of women experiencing preterm labor and intrauterine infections [25–27]. Increased IL-1–related signaling has additionally been reported in pregnancies complicated by preeclampsia, where excessive inflammatory activation and endothelial dysfunction are considered central pathogenic mechanisms. Experimental studies suggest that IL-1 may contribute to trophoblast dysfunction, impaired placental vascular remodeling, and exaggerated maternal inflammatory responses observed in hypertensive pregnancy disorders [28, 29]. These findings are generally consistent with our observations and may support a role for IL-1α in placental inflammatory responses associated with distress acuta. When comparing preterm delivery groups, it is important to note that both IL-1α and IL-1β have been reported to stimulate myometrial contractions [30]. IL-1α, which is known to be upregulated by various inflammatory stimuli, remains biologically active without requiring proteolytic processing [5]. Previous studies have demonstrated that exposure of human placental explants to hypoxic conditions may increase the production of tumor necrosis factor alpha (TNFα) and IL-1α [31], suggesting that localized ischemia or hypoxia due to impaired uterine vascular remodeling could enhance interleukin release. Similar hypoxia-associated inflammatory activation has also been described in placentas from pregnancies complicated by fetal distress and placental insufficiency, where oxidative stress and inflammatory mediator release may contribute to fetal compromise [32]. Consequently, both sterile and infectious stimuli leading to cellular damage may result in the release of bioactive IL-1α, which can signal through IL-1R to activate downstream inflammatory pathways. IL-1R, expressed in various cell types, is involved in the activation of nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK), potentially promoting the expression of pro-inflammatory mediators such as cyclooxygenase type-2 (COX-2), IL-6, and tumor necrosis factor (TNF) [33]. These pathways may contribute to the amplification of inflammatory responses and have been implicated in both preterm labor and placental dysfunction. The interaction and co-localization of IL-1 and IL-1R in both normal and inflamed placental tissues may reflect a complex balance between pro-inflammatory and anti-inflammatory mechanisms, potentially influencing both parturition and inflammatory processes. Furthermore, IL-1α has been associated with mechanisms of human parturition during infection, with its production by trophoblasts observed during early pregnancy and at term, showing a gradual decline over gestation [34]. Similar gestational trends have also been reported in studies evaluating inflammatory activation in spontaneous preterm birth and fetal inflammatory response syndrome, further supporting the potential involvement of IL-1α in pathological placental inflammation [35]. In the present study, the number of IL-2–positive structures appeared to gradually decrease from the 28th to the 40th delivery week, which may suggest that placentas from earlier gestational stages exhibit relatively higher responsiveness to this interleukin. An exception was observed at 31 weeks of gestation, where an increase in IL-2–positive macrophages was noted. It may be hypothesized that Hofbauer cells, due to their phagocytic and secretory functions and potential sensitivity to IL-2 receptor–mediated signaling, could contribute to inflammatory processes in placentas affected by distress acuta. However, this interpretation should be made with caution. Increased activation of placental macrophages and altered immune signaling have also been described in pregnancies complicated by preterm birth and preeclampsia, where excessive inflammatory activation at the maternal–fetal interface may contribute to placental dysfunction and impaired fetal well-being [36, 37]. Interestingly, previous studies have reported findings that differ from our observations, indicating that IL-2 does not enhance interferon-gamma (IFN-γ) secretion by cultured decidual macrophages, although it may synergistically stimulate IFN-γ release in decidual large granular lymphocytes [38]. Other studies have demonstrated the presence of molecules with antigenic similarity to IL-2 in the human trophoblast [39], suggesting that IL-2 may have a role in regulating local immune responses at the maternal–fetal interface [40]. Elevated IL-2 concentrations have been reported during the second and third trimesters, as well as in cases of preterm labor without chorioamnionitis, which may be partially consistent with our findings [41]. Similar increases in T-cell–associated inflammatory signaling have also been described in pregnancies complicated by fetal inflammatory response syndrome and placental inflammation, suggesting that IL-2–related pathways may contribute to inflammatory activation during complicated pregnancies [42]. In addition, IL-2 is known to promote T lymphocyte proliferation, which could contribute to immunomodulatory processes within the placenta. Some authors have identified IL-2 receptors and IL-2–related reactivity in extraembryonic membranes, including in placental tissues following spontaneous abortion [43]. Furthermore, IL-2 has been described as a stimulator of decidual natural killer (NK) cell proliferation, suggesting a possible involvement in intrauterine inflammatory responses [44]. Altered NK-cell activity and dysregulated maternal immune tolerance have also been implicated in preeclampsia and recurrent pregnancy complications, potentially linking IL-2 signaling to pathological immune activation within placental tissues [45]. However, the precise in vivo role of IL-2 remains incompletely understood, as IL-2 has not been consistently detected during implantation or in the non-pregnant endometrium [46]. Therefore, although our findings may suggest the involvement of IL-2 in inflammatory placental responses associated with distress acuta, further studies are necessary to better define its biological significance and regulatory role during complicated pregnancies. In the present study, the number of IL-7–positive structures appeared to be lower compared to other pro-inflammatory interleukins analyzed. Interestingly, across all three gestational periods, IL-7 expression was predominantly localized to Hofbauer cells. Human peripheral blood monocytes stimulated by IL-7 have been shown to produce inflammatory mediators such as IL-1α, IL-1β, IL-6, and macrophage inflammatory protein 1 beta (MIP-1β), highlighting its potential involvement in inflammatory immune responses [47]. However, this role appears to be less evident in placental tissue. Previous studies investigating decidual IL-7 expression in cases of spontaneous and recurrent spontaneous abortions have identified IL-7–positive cells in the decidua of affected patients, while the trophoblast-specific marker human leukocyte antigen-G (HLA-G) did not demonstrate IL-7 expression [48]. These findings may suggest that IL-7 is not a primary interleukin involved in the pathogenesis of distress acuta. Conversely, other studies have reported increased IL-7 immunohistochemical staining in extravillous trophoblasts and syncytiotrophoblasts of placentas from patients with gestational diabetes mellitus compared to healthy controls. This elevated expression has been associated with low-grade inflammation and altered placental differentiation processes [49]. In our study, IL-7 expression appeared relatively consistent across groups and did not demonstrate a clear association with inflammatory patterns. IL-7 has also been reported to enhance human chorionic gonadotropin (hCG) expression, thereby supporting trophoblast invasion [50]. Furthermore, reduced expression of the IL-7 receptor (IL-7R) in endometrial stromal cells of patients with recurrent spontaneous abortion has been linked to disruptions in IL-7/IL-7R signaling, which may impair trophoblast invasion [51]. Taken together, these findings may indicate that IL-7 has a more limited or context-dependent role in placental immune regulation. In the present study, the number of IL-8–positive structures did not appear to increase with advancing gestational age. This observation may suggest that IL-8 expression is relatively stable across different stages of placental development. It could also reflect a potentially higher responsiveness of earlier gestational placentas to inflammatory stimuli, although such responses may persist in distress acuta regardless of gestational age. It is important to consider that deliveries at 28 weeks are classified as premature and may be associated with various contributing factors, including infections, uterine anomalies, gynecological and obstetric history, or stress. Therefore, the observed IL-8 expression patterns may reflect a combination of underlying conditions rather than a single causative mechanism. The relatively high IL-8 activity observed in both preterm and term placental samples may be related to its role in host defense. IL-8 is known to promote neutrophil recruitment and activation, thereby contributing to inflammatory and immune responses. Placental and decidual cells have been shown to increase IL-8 secretion in response to IL-1 and tumor necrosis factor alfa (TNF-α) [52]. In the present study, trophoblast cells demonstrated the highest IL-8 positivity, particularly within the cytotrophoblast, which is consistent with previous findings indicating that IL-8 production is constitutive in trophoblasts and macrophage-like cells and may peak during the second trimester and at term [53]. Additionally, term placentas have been reported to produce IL-8, primarily localized in perivascular regions of the villi, with increased production observed following spontaneous labor [54]. These observations may suggest that IL-8 contributes to inflammatory signaling pathways associated with placental function and possibly to mechanisms involved in parturition. In the present study, IL-4 expression was largely absent in preterm placental structures, with only occasional positivity observed. This pattern may reflect a relative predominance of pro-inflammatory interleukins, which could potentially influence or limit the anti-inflammatory activity of IL-4 during inflammatory conditions. In contrast, term placental samples demonstrated comparatively higher IL-4 expression. These findings are generally consistent with previous studies reporting increased IL-4 and IL-10 production in normal pregnancies, whereas reduced levels of these interleukins have been associated with pathological pregnancies [55]. Reduced anti-inflammatory signaling has also been described in pregnancies complicated by preeclampsia, spontaneous preterm birth, and placental inflammatory disorders, where excessive maternal immune activation may contribute to endothelial dysfunction and impaired placental homeostasis [56, 57]. In addition, lower IL-4 levels have been linked to increased natural killer (NK) cell activity in women with recurrent spontaneous abortions and preeclampsia [58, 59]. Experimental studies in IL-4–deficient mice have demonstrated alterations in immune cell populations, elevated pro-inflammatory interleukin levels, placental inflammation, hypertension, and endothelial dysfunction [60]. These observations may support a potential role for IL-4 in maintaining immunological balance during pregnancy. Furthermore, impaired anti-inflammatory regulation has been proposed as an important contributor to placental dysfunction and fetal compromise in inflammatory pregnancy conditions, including fetal distress and placental insufficiency [61]. Earlier studies have also identified IL-4 expression in placental endothelial cells, macrophages, and cytotrophoblasts [62, 63], suggesting that its activity may vary between cell types and may contribute to protective or regulatory functions within the placenta. Similar findings have been reported in studies investigating maternal–fetal immune tolerance, where IL-4 has been associated with the maintenance of a predominantly anti-inflammatory intrauterine environment necessary for successful pregnancy progression [64]. However, other studies examining interleukin and growth factor profiles in pregnancies with and without preeclampsia have reported no significant differences in IL-4 levels [65], indicating that its role in certain pathological processes may be limited or context-dependent. Therefore, although the reduced IL-4 expression observed in the present study may reflect altered anti-inflammatory regulation in placentas affected by distress acuta, additional studies are necessary to clarify its precise functional significance in pathological pregnancy conditions. In the present study, the number of IL-10–positive structures was markedly reduced, with only occasional immunopositivity observed in both preterm and term placental samples. Slightly greater variability in IL-10 expression was noted in the extraembryonic mesoderm and Hofbauer cells. Overall, IL-10 activity appeared to be low across the analyzed groups, including term and control placentas. Previous studies have reported reduced IL-10 levels in placental tissues associated with chorioamnionitis-related preterm labor and term labor, compared to second-trimester placental samples obtained from elective terminations [66]. These findings are generally consistent with the reduced IL-10 expression observed in our study and may reflect its involvement in inflammatory processes. Reduced anti-inflammatory signaling has also been described in pregnancies complicated by fetal inflammatory response syndrome, placental insufficiency, and preeclampsia, where excessive inflammatory activation may contribute to impaired placental homeostasis and adverse pregnancy outcomes [13, 67]. Existing data indicate that IL-10 levels are higher in first- and second-trimester placental tissues compared to third-trimester tissues, suggesting a physiological downregulation of IL-10 toward term, potentially associated with the development of a pro-inflammatory environment preceding labor [68]. This pattern may partially align with our observations. Similar gestational changes in anti-inflammatory interleukin expression have also been described in spontaneous preterm birth, supporting the concept that altered immune regulation may contribute to pathological labor processes [69]. Additionally, IL-10 has been described as an important regulatory interleukin at the maternal–fetal interface. Reduced IL-10 production has been observed in placental and decidual tissues from first-trimester missed abortions compared to control tissues from elective terminations [70]. Conversely, increased IL-10 expression has been reported in term placentas from women with preeclampsia [71], suggesting that its role may vary depending on the specific pathological context. This variability may reflect compensatory anti-inflammatory responses occurring in some inflammatory pregnancy disorders. Furthermore, reduced IL-10 expression in term placentas not in labor, compared to earlier gestational stages, has been interpreted as part of physiological changes associated with the initiation of labor [72]. However, the extent to which this mechanism contributes to pathological conditions remains unclear. Reduced IL-10 production has also been associated with adverse pregnancy outcomes, as placental explants from women experiencing preterm labor have demonstrated lower IL-10 levels compared to normal pregnancies [66]. Similar findings have been described in studies of pregnancies complicated by fetal distress and placental inflammatory injury, where diminished anti-inflammatory regulation may contribute to excessive immune activation and tissue damage [73]. Taken together, these observations may support the possibility that reduced IL-10 activity contributes to altered immune regulation in placentas affected by distress acuta. Nevertheless, further studies are necessary to better clarify the precise role of IL-10 in inflammatory placental pathology and complicated pregnancies. In the present study, IL-6 expression appeared relatively consistent in the extraembryonic mesoderm, macrophages, and endothelial cells across all three gestational groups, with some individual variability. This pattern may suggest that IL-6 has a relatively stable role in placental function across different stages of gestation. Previous studies similarly highlight the importance of IL-6, as its concentrations have been shown to increase in human amniotic fluid, vaginal fluid, cervical fluid, maternal circulation, and fetal tissues in response to feto-placental infections [74]. Both clinical and experimental evidence indicates that IL-6 signaling may be activated in multiple placental compartments during intrauterine inflammation. Amnion mesenchymal cells and decidual stromal cells have been identified as important sources of IL-6 under such conditions, potentially contributing to the processes associated with preterm labor [75]. In addition, correlation analyses have demonstrated a positive association between IL-6 expression levels and the development of bronchopulmonary dysplasia, a common complication in premature infants [72]. However, other studies suggest that chorioamnionitis may not significantly influence the immunohistochemical expression of IL-6 in placental membranes of women with late preterm deliveries, regardless of clinical presentation [76]. These observations reflect the complexity of IL-6 function, as it can exhibit both pro-inflammatory and anti-inflammatory properties. This dual role depends on the type of receptor involved (soluble or transmembrane) and the associated signaling pathways [77]. IL-6 is produced by human trophoblasts and has been associated with multiple physiological processes, including vascular regulation, trophoblast growth, invasion and differentiation, as well as modulation of placental hormone production and angiogenesis [9]. Taken together, these findings may indicate that IL-6 contributes to maintaining placental homeostasis, and its expression may remain relatively stable even under varying physiological and pathological conditions. However, further studies are required to better understand its precise role. Both positive and negative correlations were identified among the studied interleukins across different placental structures, including cytotrophoblasts, extraembryonic mesoderm, macrophages, and endothelial cells. It is important to emphasize that correlation does not imply causation; therefore, these findings should not be interpreted as evidence of direct causal relationships between the examined interleukins. Nevertheless, the observed associations may suggest potential synergistic or antagonistic interactions within the placental interleukin network. Within the cytotrophoblast, a negative correlation between IL-7 and IL-1α may indicate that increased IL-7 expression is associated with lower IL-1α levels, suggesting a possible regulatory relationship between these interleukins. Similarly, the negative correlation observed between IL-2 and IL-4 may reflect a balance between pro-inflammatory and anti-inflammatory signaling, potentially indicating reduced anti-inflammatory activity in the presence of increased IL-2 expression. In the extraembryonic mesoderm, a positive correlation between IL-6 and IL-1α may suggest that these pro-inflammatory interleukins tend to increase concurrently, which could be associated with inflammatory processes within this placental compartment. Conversely, the negative correlation between IL-2 and IL-4 may further support the presence of a regulatory balance between pro- and anti-inflammatory interleukins. Additionally, the positive association between IL-10 and IL-8 may indicate a potential compensatory response, in which anti-inflammatory activity increases alongside elevated inflammatory signaling. Within macrophages, several positive correlations were observed. The association between IL-2 and IL-1α may suggest coordinated activity between these pro-inflammatory interleukins, potentially reflecting enhanced immune responsiveness. Positive correlations between IL-7 and IL-1α, as well as between IL-7 and IL-2, may indicate coordinated expression patterns that could be involved in immune regulation and tissue responses. Additional associations involving IL-8 and IL-2, IL-6 and IL-2, and IL-10 and IL-7 further highlight the complexity of interleukin interactions within macrophages, suggesting the simultaneous involvement of pro-inflammatory and anti-inflammatory pathways. In contrast, no statistically significant correlations between the studied interleukins were identified within endothelial cells. This finding may suggest that endothelial structures have a more limited or less detectable role in the interleukin-related regulatory dynamics observed in the present study. Cross-structural analysis revealed multiple strong correlations for several interleukins—including IL-1α, IL-2, IL-6, IL-7, IL-8, IL-4, and IL-10—across different placental cell types, including cytotrophoblasts, extraembryonic mesoderm, macrophages, and endothelial cells. These associations may suggest coordinated inflammatory and regulatory responses across placental compartments. Overall, these findings may indicate the presence of a complex interplay between pro-inflammatory and anti-inflammatory interleukins during pregnancy. The observed relationships may reflect mechanisms aimed at maintaining an appropriate inflammatory balance within placental tissues. Such regulation could be important for preventing excessive inflammatory responses that might adversely affect placental function, fetal development, and pregnancy outcomes. One of the main limitations of the present study is the absence of gestational age–matched control groups for each of the analyzed time points. Ideally, the inclusion of control placental samples at 28 and 31 weeks of gestation would allow a more precise distinction between physiological developmental changes and alterations associated with placental distress. However, due to ethical constraints, control placental tissues could only be obtained from term deliveries (40 weeks of gestation). Therefore, potential differences between study groups may partly reflect gestational age–related variation rather than solely pathological processes, and this should be considered when interpreting the findings. Another important limitation is the relatively small sample size, with five cases per group and five controls. This restricts statistical power and limits the robustness of comparative and correlational analyses, particularly given the evaluation of multiple interleukins across several placental compartments. The study was designed as a pilot, exploratory investigation aimed at identifying potential expression patterns rather than establishing definitive statistical associations. In morphological and histological studies involving unique human tissue samples, such sample sizes are not uncommon due to limited availability and ethical considerations. Nevertheless, the findings should be interpreted with caution, and larger-scale studies are required to confirm these observations. In addition, the semi-quantitative nature of the immunohistochemical assessment represents a methodological limitation. Although widely used in morphological research, this approach relies on visual scoring and may introduce a degree of subjectivity. To minimize this, evaluations were performed independently by two experienced morphologists with subsequent consensus; however, some variability cannot be entirely excluded. Another limitation relates to the retrospective design of the study. The placental samples were obtained from archived material originally collected as part of routine clinical care and previous research projects. Although all samples were processed and stored under standardized conditions (formalin fixation and paraffin embedding), potential preanalytical variability over time cannot be completely ruled out. Furthermore, the absence of stratified analyses by gestational age represents an additional limitation. Although gestational age is a central variable in the study, subgroup-specific correlation analyses were not performed due to the limited number of samples within each group, which would result in statistically underpowered and potentially unreliable outcomes. A further limitation is the lack of formal statistical comparison of clinical and sociodemographic characteristics between study groups. Although variables such as maternal age, graviditas, and partus are presented, the small sample size precluded reliable statistical testing. Consequently, potential residual confounding factors—including maternal age, reproductive history, underlying conditions, or other unmeasured variables—cannot be fully excluded. Therefore, differences in interleukin expression may be influenced not only by placental distress but also by underlying group heterogeneity. Furthermore, an additional limitation relates to the clinical definition of acute fetal distress (distress acuta). Although all cases were retrospectively selected from clinically confirmed diagnoses documented in obstetric medical records and evaluated according to recognized intrapartum fetal monitoring principles, universally standardized diagnostic criteria for acute fetal distress remain limited. The diagnosis relied primarily on clinical interpretation of cardiotocographic abnormalities, reduced fetal well-being, suspected fetal hypoxia, and indications for urgent obstetric intervention. Therefore, some degree of clinical heterogeneity between cases cannot be entirely excluded, which should be considered when interpreting the findings. In addition, correlation analyses performed in this study should be interpreted cautiously, as correlation does not imply causation. The observed associations reflect potential relationships between interleukins but do not provide evidence of direct mechanistic interactions. Finally, the study relied primarily on immunohistochemical methods for the assessment of interleukin expression. Although this approach allows localization within tissue structures, it does not provide precise quantitative measurement of protein concentrations. Complementary techniques, such as Western blotting or enzyme-linked immunosorbent assay, could provide additional quantitative validation and should be considered in future studies. Moreover, further investigations focusing on molecular mechanisms, including gene expression and regulatory pathways of interleukins in placental tissues, would help to better understand their role in placental physiology and pathology. Conclusions The present study suggests that placental distress acuta is associated with altered interleukin expression patterns across different placental compartments. Increased expression of pro-inflammatory interleukins, particularly IL-1α, IL-2, and IL-8, together with reduced anti-inflammatory interleukins such as IL-4 and IL-10, may indicate a shift toward a pro-inflammatory environment in affected placentas. IL-6 expression appeared relatively stable across gestational stages, suggesting a potential regulatory role in maintaining placental function. In contrast, control placentas at 40 weeks demonstrated a more balanced interleukin profile, characterised by lower pro-inflammatory activity and relatively higher anti-inflammatory expression. Overall, these findings may reflect an imbalance in local immune regulation in placental distress acuta. However, given the exploratory nature of the study, the results should be interpreted with caution, and further research is required to confirm these observations. Acknowledgements Doctor Ilze Kreicberga is kindly acknowledged for the providing of the material and Laboratory Assistant Natalia Moroza for the technical support. Authors’ contributions Conceptualization, E.B. and M.P.; methodology, M.P.; software, E.B.; validation, E.B., M.P., J.B. and A.J.; formal analysis, E.B.; investigation, E.B.; resources, M.P.; data curation, M.P.; writing—original draft preparation, E.B.; writing—review and editing, E.B., M.P., J.B. and A.J.; visualization, E.B.; supervision, M.P.; project administration, M.P.; funding acquisition, M.P. All authors have read and agreed to the published version of the manuscript. Funding This research received no external funding. Data availability All data generated or analysed during this study are included in this published article. Declarations Ethics approval and consent to participate The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Riga Stradins University (12 March 2003). Written informed consent for participation was obtained from all participants. Consent for publication Written informed consent for the publication of anonymized data was obtained from all participants. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement All data generated or analysed during this study are included in this published article.